Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Budesonide orodispersible - Dr Falk Pharma

Next Previous
Drug Profile

Budesonide orodispersible - Dr Falk Pharma

Alternative Names: Budesonide orodispersible tablets - Dr Falk Pharma; BUET; Jorveza

Latest Information Update: 05 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dr Falk Pharma
  • Class Alcohols; Anti-inflammatories; Antiallergics; Antiasthmatics; Antivirals; Dioxoles; Glucocorticoids; Pregnenediones; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Eosinophilic oesophagitis
  • New Molecular Entity No

Highest Development Phases

  • Marketed Eosinophilic oesophagitis
  • Phase III Graft-versus-host disease
  • Phase II Gastrointestinal disorders

Most Recent Events

  • 05 Feb 2026 Budesonide orodispersible is still in phase III trials for Eosinophilic oesophagitis in Germany, Portugal, Spain and Austria ((CTIS-2020-001314-37))
  • 18 May 2024 Adverse event data from the phase III trial in Eosinophilic oesophagitis presented at the Digestive Disease Week 2024 (DDW-2024)
  • 12 Oct 2022 Phase-III clinical trials in Eosinophilic oesophagitis in Portugal (PO) (CTIS-2020-001314-37)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top